European league against rheumatism/European vasculitis study group recommendations for the management of vasculitis

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 49-53

  Villa Forte, Alexandra ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Arteritis; Cyclophosphamide; European League Against Rheumatism; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; RIBAVIRIN; RITUXIMAB;

AORTA ARCH SYNDROME; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDICATION; GIANT CELL ARTERITIS; HEPATITIS C ASSOCIATED CRYOGLOBULINEMIC VASCULITIS; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MEDICAL SOCIETY; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

BLOOD VESSELS; CLINICAL PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; HEPATITIS; HUMANS; IMMUNOTHERAPY; MEDICINE; QUALITY OF HEALTH CARE; SYSTEMIC VASCULITIS; VASCULAR SURGICAL PROCEDURES;

EID: 73649149078     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328332c9d1     Document Type: Review

References (34)

1. Mukhtyar C, Guillevin L, Cid M, et al. Eular recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
2. Mukhtyar C, Guillevin L, Cid M, et al. Eular recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68:318-323.
3. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111:507-513.
4. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 2003; 49:151-155.
5. Choi HK, Liu S, Merkel PA, et al. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 2001; 28:1584-1590.
6. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632-638.
7. Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis: Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 15:315-333.
8. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine 1973; 52:535-561.
9. Magrey M, Villa-Forte A, Koening C, et al. Therapeutic dilemma: persistent hematuria after induction of remission in Wegener granulomatosis. Medicine (in press).
10. De Groot K, Rasmussen N, Bacon P, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461-2469.
11. Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: A 12-year single-practice experience. Medicine 2007; 86:269-277.
12. De Groot K, Adu D, Savage CO, et al. The value of pulse cyclophosphamide in ANCA-associated vasculitis meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018-2027.
13. De Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplsmic antibodyassociated vasculitis. Ann Intern Med 2009; 150:670-680.
14. Jayne D, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188.
15. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's Granulomatosis. Rheumatology 2007; 46:1087-1091.
16. Pagnoux C, Mahr A, Amidou M, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790-2803.
17. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021-1032.
18. Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: A prospective randomized trial of 71 patients. The cooperative study group for polyarteritis nodosa. J Rheumatol 1991; 18:567-574.
19. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
20. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58:308-317.
21. Rituximab for the treatment of Wegener's granulomatosis and microscopic polyangiitis (RAVE). ClinicalTrials.gov Identifier: NCT00104299.
22. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611-619.
23. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36:365-371.
24. Levine JW, Gota C, Fessler BJ, et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32:1164-1167.
25. Gabriel SE, O'Fallon MW, Achkar AA, et al. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22:93-96.
26. Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Int Med 1975; 82:613-618.
27. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum 2007; 56:2789-2797.
28. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, doubleblind, placebo-controlled trail of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46:1309-1318.
29. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. Ann Intern Med 2007; 164:621-630.
30. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatic: A randomized trial. Ann Intern Med 2007; 146:631-639.
31. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50:1332-1337. (Pubitemid 38480844)
32. Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54:3306-3309.
33. Hoffman GS, Merkel PA, Brasington RD, et al. Antitumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50:2296-2304.
34. Molloy ES, Langford CA, Clark TM, et al. Antitumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67:1567-1569.